<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="87081">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01971515</url>
  </required_header>
  <id_info>
    <org_study_id>EMR100018-001</org_study_id>
    <nct_id>NCT01971515</nct_id>
  </id_info>
  <brief_title>First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies</brief_title>
  <official_title>A Phase I, First-in-Human, Dose Escalation Trial of MSC2363318A, a Dual p70S6K/Akt Inhibitor, in Subjects With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMD Serono</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMD Serono</source>
  <brief_summary>
    <textblock>
      This is a Phase 1, first-in-human, open-label, non-randomized, dose escalation, trial to
      explore the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and clinical
      activity signals of MSC2363318A.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of dose limiting toxicities (DLTs) in Dose Escalation and Trastuzumab or Tamoxifen combination arms</measure>
    <time_frame>Up to Day 21 of Cycle 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with Treatment-emergent adverse events (TEAEs), Serious Adverse Events (SAEs), and deaths in cohort for subjects with PAM pathway alterations</measure>
    <time_frame>Baseline up to Day 30 after the last dose of study treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Observed Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Days 1, 2, 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2, Cycle 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To Reach Maximum Plasma Concentration (Tmax)</measure>
    <time_frame>Days 1, 2, 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2, Cycle 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Plasma Concentration Versus Time Curve From Time Zero to Last Sampling Time (AUC0-t)</measure>
    <time_frame>Days 1, 2, 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2, Cycle 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf)</measure>
    <time_frame>Days 1, 2, 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2, Cycle 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Plasma Concentration Versus Time Curve Within One Dosing Interval (AUCtau)</measure>
    <time_frame>Days 1, 2, 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2, Cycle 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Half-life ( t1/2)</measure>
    <time_frame>Days 1, 2, 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2, Cycle 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Oral Clearance (CL/F)</measure>
    <time_frame>Days 1, 2, 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2, Cycle 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Oral Clearance Steady State (CLss/F)</measure>
    <time_frame>Days 1, 2, 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2, Cycle 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F)</measure>
    <time_frame>Days 1, 2, 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2, Cycle 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution at Steady State (Vss/F)</measure>
    <time_frame>Days 1, 2, 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2, Cycle 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Factor to Assess the Increase of Drug Concentration in Plasma Until Steady State is Reached [Racc(AUC)]</measure>
    <time_frame>Days 1, 2, 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2, Cycle 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Factor to Assess the Maximal Increase of Drug Concentration in Plasma [Racc (Cmax)]</measure>
    <time_frame>Days 1, 2, 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2, Cycle 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with best overall response according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v 1.1) or Cheson 2007</measure>
    <time_frame>Evaluation were performed on Day 1 of every alternate cycle until tumor progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with clinical benefit</measure>
    <time_frame>Week 12</time_frame>
    <description>Percentage of subjects with clinical benefit is defined as subjects with complete response (CR) or partial response (PR) at week 12, based on tumor assessment as determined by RECIST version 1.1 or Cheson 2007.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR) for Cohort 2 only</measure>
    <time_frame>Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) rate for Cohorts 2 and 3 only</measure>
    <time_frame>up to 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>MSC2363318A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MSC2363318A plus Trastuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MSC2363318A plus Tamoxifen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MSC2363318A</intervention_name>
    <description>Part 1: MSC2363318A will be administered orally once daily for repeated 21-day cycles until intolerable toxicity or disease progression. Additional dose escalations will continue until Maximum Tolerated Dose (MTD) is reached, the food effect will be investigated in a separate group.
Part 2 (Cohort 1): MSC2363318A will be administered orally once daily for repeated 21-day cycles until intolerable toxicity or disease progression in subjects with PAM pathway alterations.</description>
    <arm_group_label>MSC2363318A</arm_group_label>
    <other_name>M2698</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MSC2363318A plus Trastuzumab</intervention_name>
    <description>Part 2 Cohort 2: MSC2363318A will be administered orally once daily for repeated 21-day cycles in combination with Trastuzumab. Trastuzumab is a recombinant IgGI kappa humanized monoclonal antibody administered weekly by intravenous infusion.</description>
    <arm_group_label>MSC2363318A plus Trastuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MSC2363318A plus Tamoxifen</intervention_name>
    <description>Part 2 Cohort 3: MSC2363318A will be administered orally once daily for repeated 21-day cycles in combination with Tamoxifen. Tamoxifen is a nonsteroidal antiestrogen administered daily by oral administration.</description>
    <arm_group_label>MSC2363318A plus Tamoxifen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater than or equal to (&gt;=)18 years

          -  Confirmed diagnosis of advanced malignancies that may be controlled with p70S6K or
             Akt inhibition based on already identified molecular alteration known to affect the
             PAM pathway, such as:: such as: such as: phosphate and tensin homolog (PTEN),
             phosphoinositide 3-Kinase catalytic subunit alpha isoform (PI3KCA), protein kinase B
             1 (Akt 1), Akt 3, mammalian target of rapamycin (mTOR), tumor sclerosis complex 1
             (TSC1), tumor sclerosis complex 2 (TSC2), in subjects who have received at least all
             treatment options considered to be standard therapy, unless some available treatment
             are not acceptable to the subject. For the dose escalation portion of the trial,
             subjects must have received the standard therapy unless intolerant or
             contraindicated.

               -  Part 2, Cohort 1: For subjects with PAM pathway alterations, subjects must have
                  only PAM alterations, excluding Akt2 activating mutations or amplifications, and
                  no other confounding genomic alterations.

               -  Part 2, Cohort 2: Histologically confirmed local laboratory testing
                  (immunohistochemistry 3+ staining and/or fluorescence in situ hybridization
                  ratio â‰¥ 2.0) HER2+ metastatic breast cancer subjects who are resistant to
                  trastuzumab-containing treatment and progressed on trastuzumab, pertuzumab, a
                  taxane, and/or trastuzumab emtansine. There is no limit regarding the number of
                  prior lines of therapy.

               -  Part 2, Cohort 3: Histologically and/or cytologically confirmed diagnosis of
                  breast cancer with hormone receptor-positive status (ER and/or PgR positive) and
                  HER2-negative status with prior exposure to tamoxifen and/or an aromatase
                  inhibitor and/or an aromatase inhibitor plus palbociclib. Prior treatment with
                  tamoxifen in the neoadjuvant setting is allowed but must have been discontinued
                  for at least 1 year prior to the first dose.

          -  Measurable disease using clinically appropriate criteria for the type of malignancy,
             RECIST version 1.1 for solid tumors and Cheson 2007 for lymphoma

          -  A tumor accessible for biopsies and consent to undergo tumor biopsies before and
             during MSC2363318A treatment

          -  Ability to read and understand the informed consent form and willingness and ability
             to give informed consent and demonstrate comprehension of the trial before undergoing
             any trial activities

          -  Negative blood pregnancy test at the screening visit for women of childbearing
             potential

          -  Willingness to avoid pregnancy and breast feeding beginning two weeks before the
             first MSC2363318A dose and ending three months after the last trial treatment. Male
             subjects with female partners of childbearing potential and female subjects of
             childbearing potential must use adequate contraception in the judgment of the
             Investigator, such as a two barrier method or a one barrier method with spermicide or
             intrauterine device

        Exclusion Criteria:

          -  Eastern Cooperative Oncology Group Performance Status &gt;=2

          -  Previous therapy with:

               -  Previous treatment of the currently malignancy with a PAM Pathway Inhibitor

               -  Chemotherapy, immunotherapy, hormonal therapy (except low dose corticosteroids),
                  biologic therapy, or any other anticancer therapy within 1 month (or five
                  elimination half-lives for noncytotoxics, whichever is shorter) of Day 1 of
                  trial drug treatment (6 weeks for nitrosureas or mitomycin

               -  Any investigational agent within 28 days of Day 1 of trial drug treatment

               -  Extensive prior radiotherapy on more than 30 percent of bone marrow reserves, or
                  prior bone marrow/stem cell transplantation within 5 years from enrolment

          -  Known tumor EGFR, KRAS, and/or Akt2 mutations of amplification

          -  Ongoing toxicity (except alopecia) due to a prior therapy, unless returned to
             baseline or Grade 1 or less

          -  Major surgical intervention or participation in a therapeutic clinical trial within
             28 days from Day 1 of the first dose of MSC2363318A

          -  Bone marrow impairment, renal impairment, liver function abnormality and impaired
             cardiac function as defined in the protocol

          -  History of cerebral vascular accident or stroke within the previous 2 years

          -  Uncontrolled hypertension

          -  History of Grade 3 or 4 allergic reactions attributed to compounds of similar
             chemical or biologic composition as MSC2363318A

          -  Known active central nervous system (CNS) metastases

          -  History of difficulty swallowing, malabsorption or other chronic gastrointestinal
             disease or conditions that may hamper compliance and/or absorption of the
             investigational product

          -  Known human immunodeficiency virus, viral hepatitis, or tuberculosis positivity

          -  Legal incapacity or limited legal capacity

          -  Any other condition which, in the opinion of the Investigator, might impair the
             subject's tolerance of trial treatment, the safety of the individual subject or the
             outcome of the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Remigiusz Kaleta, MD</last_name>
    <role>Study Director</role>
    <affiliation>EMD Serono, Inc., Rockland MA, a subsidiary of Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Please Contact U.S. Medical Information Located in Rockland, MA, United States</last_name>
    <phone>888-275-7376</phone>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Carla Falkson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Monica Mita, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California at San Diego, Moores Cancer Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Razelle Kurzrock, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gilberto Lopes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dejan Juric, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ding Wang, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Amy Weise, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Haeseong Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Charles Shapiro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>John Nemunaitis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Apostolia Tsimberidou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>John Sarantopoulos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fletcher Allen Health Care, Inc.</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kim Dittus, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 27, 2017</lastchanged_date>
  <firstreceived_date>October 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MSC2363318A</keyword>
  <keyword>Maximum tolerated dose</keyword>
  <keyword>Dose limiting toxicities</keyword>
  <keyword>Recommended phase 2 dose</keyword>
  <keyword>M2698</keyword>
  <keyword>Metastatic Breast Cancer</keyword>
  <keyword>HER2+ Metastatic Breast Cancer</keyword>
  <keyword>Hormone refractory ER/PR+ breast cancer</keyword>
  <keyword>Tamoxifen</keyword>
  <keyword>PAM Pathway Alteration(s)</keyword>
  <keyword>PAM Pathway</keyword>
  <keyword>Targeted Therapy</keyword>
  <keyword>P70S6K</keyword>
  <keyword>AKT Inhibition</keyword>
  <keyword>PI3K Pathway</keyword>
  <keyword>HER2+ Trastuzumab Resistance</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
